Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead Sells 10,000 Shares of Stock

Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead sold 10,000 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $7.88, for a total value of $78,800.00. Following the completion of the sale, the chief financial officer now owns 26,299 shares of the company’s stock, valued at $207,236.12. This trade represents a 27.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Zynex Price Performance

Shares of ZYXI opened at $8.09 on Friday. The company’s fifty day simple moving average is $8.30 and its 200 day simple moving average is $8.37. Zynex, Inc. has a 1-year low of $7.15 and a 1-year high of $13.77. The company has a market cap of $257.63 million, a price-to-earnings ratio of 53.93 and a beta of 0.49. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66.

Zynex (NASDAQ:ZYXI) last announced its quarterly earnings results on Thursday, October 24th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The firm had revenue of $49.97 million for the quarter, compared to the consensus estimate of $50.83 million. During the same quarter in the previous year, the business earned $0.10 earnings per share. The business’s revenue was up .1% compared to the same quarter last year. On average, research analysts forecast that Zynex, Inc. will post 0.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zynex

Hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC raised its position in shares of Zynex by 68.7% in the second quarter. Renaissance Technologies LLC now owns 189,762 shares of the company’s stock valued at $1,769,000 after purchasing an additional 77,300 shares during the period. Millennium Management LLC raised its holdings in Zynex by 66.5% in the 2nd quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock valued at $2,769,000 after acquiring an additional 118,615 shares during the period. Quest Partners LLC lifted its position in Zynex by 646.7% during the second quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock worth $120,000 after acquiring an additional 11,195 shares during the last quarter. Principal Financial Group Inc. lifted its position in Zynex by 10.4% during the second quarter. Principal Financial Group Inc. now owns 19,525 shares of the company’s stock worth $182,000 after acquiring an additional 1,846 shares during the last quarter. Finally, American Century Companies Inc. boosted its holdings in shares of Zynex by 10.1% during the second quarter. American Century Companies Inc. now owns 31,159 shares of the company’s stock worth $290,000 after acquiring an additional 2,864 shares during the period. Institutional investors and hedge funds own 29.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on ZYXI shares. Royal Bank of Canada cut their price target on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Zynex in a research report on Friday, December 6th.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.